



EZ-Tn5™ <R6K γ ori/KAN-2>Tnp Transposome™ Kit

Cat. No. TSM08KR

Available exclusively thru Lucigen.
lucigen.com/epibio

epicentre®
an Illumina® company

1. Introduction

The EZ-Tn5™ <R6K*Yori*/KAN-2> Tnp Transposome™ is the stable complex formed between the EZ-Tn5 Transposase enzyme and the EZ-Tn5 <R6K*Yori*/KAN-2> Transposon. The EZ-Tn5 <R6K*Yori*/KAN-2> Transposon contains an R6K γ conditional origin of replication (R6K*Yori*) and the Tn903 kanamycin resistance gene (KanR) that is functional in *E. coli*, flanked by hyperactive 19-basepair Mosaic End (ME) EZ-Tn5 Transposase recognition sequences. The EZ-Tn5 Transposome can be electroporated into living cells where the EZ-Tn5 Transposase is activated by Mg²⁺ in the host's cellular environment resulting in random insertion of the EZ-Tn5 Transposon into the genomic DNA of the host.^{1,2}

The R6K*Yori* makes this transposon useful for "rescue cloning" of the region of genomic DNA into which the transposon has been randomly inserted. An overview of the rescue cloning process is presented on page 2. Genomic DNA transposed with the EZ-Tn5 <R6K*Yori*/KAN-2> Transposon is first purified and then fragmented, self-ligated and finally transformed into an *E. coli* host that expresses the *pir* gene product (the "pi" protein).³ When selected on kanamycin-containing plates, only the cells containing the <R6K*Yori*/KAN-2> Transposon will grow.

Unlabeled forward and reverse transposon-specific primers are supplied in the kit. These primers can be used for bidirectional DNA sequencing or mapping of transposon insertion sites in target genomic DNAs or rescue clones.

2. Product Designations and Kit Components

Product	Kit Size	Catalog Number	Reagent Description	Part Numbers	Volume
EZ-Tn5 <R6K <i>Yori</i> /KAN-2> Tnp Transposome Kit	10 Rxns	TSM08KR	EZ-Tn5 <R6K <i>Yori</i> /KAN-2> Tnp Transposome (0.1 pmol/ μ L)	SS000590-D	10 μ L
			KAN-2 FP-1 Forward Primer (50 μ M)	SS000523-D	20 μ L
			R6KAN-2 RP-1 Reverse Primer (50 μ M)	SS000536-D	20 μ L
			Nuclease-Free Water, Sterile	SS000772-D3	1 mL

3. Product Specifications

Storage: Store only at -20°C in a freezer without a defrost cycle.

Size: Reagents included in the kit are sufficient for 10 *in vivo*[†] transposon insertion reactions.

Storage Buffer: The EZ-Tn5 <R6K*Yori*/KAN-2> Tnp Transposome is supplied in a 50% glycerol solution containing 27.5 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.3 mM EDTA, 0.05% Triton®X-100, and 0.5 mM dithiothreitol. The KAN-2 FP-1 Forward Primer and R6KAN-2 RP-1 Reverse Primer are supplied in 10 mM Tris-HCl, (pH 7.5), 1 mM EDTA.




Figure 1. Rescue Cloning Overview.

Quality Control: EZ-Tn5 <R6K_{Yori}/KAN-2>Tnp Transposome activity is assayed by electroporation into a *recA*⁻ *E. coli* host strain having a transformation efficiency of >10⁹ cfu/μg DNA. Assays must yield >10⁵ Kan^R colonies/μg or >2.0 x 10³ Kan^R colonies/μL of transposome respectively. Primers are function-tested via PCR and in a DNA cycle sequencing reaction and a plasmid containing an EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon as template.

Contaminating Activity Assays: All components of the EZ-Tn5 <R6K_{Yori}/KAN-2>Tnp Transposome Kit are free of detectable DNase and RNase activities as judged by agarose gel electrophoresis following over-digestion assays with the exception of the inherent endonucleolytic function of the EZ-Tn5 Transposase.

4. Rescue Cloning of EZ-Tn5 <R6K_{Yori}/KAN-2> Transposed Genomic DNA

An overview of the process for rescue cloning of the EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon insertion site in genomic DNA is given below.

Protocol

- 1. Electroporation of Host Cells with EZ-Tn5 <R6K_{Yori}/KAN-2>Tnp Transposome and Selection of Transposition Clones:** Electroporate electrocompetent cells using 1 μL of the EZ-Tn5 <R6K_{Yori}/KAN-2>Tnp Transposome. The electrocompetent cells should have a transformation efficiency of >10⁷ cfu/μg of DNA, but use cells of the highest transformation efficiency possible to maximize the number of transposon insertion clones. Perform electroporation according to the equipment manufacturer's recommendations.

Immediately recover the electroporated cells after electroporation. Even slight delays in initiating the cell recovery process will result in a reduced number of transposition clones. For *E. coli*, add SOC medium to the electroporation cuvette to 1 mL final volume **immediately** after electroporation. Pipette the medium/cells gently to mix. Transfer to a tube and incubate on a 37°C shaker for 30-60 minutes to facilitate cell outgrowth.

If working with *E. coli*, dilute aliquots of the recovered cells (e.g., 1:10 and 1:100). Plate 100 µL of undiluted cells and each cell dilution separately on plates containing 50 µg/mL kanamycin. Other species may require plating of undiluted cells on plates containing 25-50 µg/mL kanamycin. Store the unused portion of the electroporated cells at +4°C for up to 2 days in the event that additional plates need to be prepared. The number of Kan^R colonies/µL of EZ-Tn5 <R6K_{Yori}/KAN-2>Tnp Transposome will be dependent on the transformation efficiency of the cells used and the level of expression of the Tn903 kanamycin resistance marker in that species. Select transposition clones for "rescue cloning" by any of a number of methods including observing a desired phenotypic change, Southern Blot analysis or selecting for a desired "gene knockout".

2. **Preparation of Transposed Genomic DNA from Host Cells:** Prepare genomic DNA from chosen clones, using a bacterial genomic DNA purification kit or protocol. Fragment 1 µg of the genomic DNA by random shearing or by restriction endonuclease digestion(s) (See page 5 for the restriction map of the EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon in order to avoid restriction within the transposon). If desired, size-select the fragmented genomic DNA (e.g., by low-melting point agarose gel electrophoresis). Genomic DNA that has been fragmented by random shearing or by digestion with two different restriction endonucleases must be end-repaired (made blunt-ended) and 5'-phosphorylated in order to be self-ligated. End-repair and 5'-phosphorylate the DNA as necessary (e.g., by using the End-It™ DNA End-Repair Kit [Lucigen]).
3. **Ligation of Fragmented Genomic DNA:** Self-ligate 0.1-1 µg of DNA using 2 U of T4 DNA Ligase in 10-20 µL total volume for 1 hour at room temperature. The extent of ligation can be quickly monitored by running aliquots of the reaction before and after addition of the T4 DNA Ligase addition, on an agarose gel. Terminate the reaction and inactivate the T4 DNA Ligase by heating at 70°C for 10 minutes.
4. **Transformation and Selection of Rescue Clones:** Electroporate electrocompetent *pir E. coli* (*E. coli* expressing the Π protein, e.g. TransforMax EC100D *pir*⁺ or TransforMax EC100D *pir*-116 Electrocompetent *E. coli*) using 1-2 µL of the ligation mix. Recover the electroporated cells by adding SOC medium to the electroporation cuvette to 1 mL final volume **immediately** after electroporation. Pipette the medium/cells gently to mix. Transfer to a tube and incubate on a 37°C shaker for 30-60 minutes to facilitate cell outgrowth. Plate cells on LB agar containing 50 µg/mL of kanamycin. Select Kan^R colonies overnight.
5. **DNA Sequencing of Rescue Clones:** Unlabeled forward and reverse EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon-specific primers are supplied in the kit. These primers can be used for bidirectional DNA sequencing or mapping of transposon insertion sites in target genomic DNAs or rescue clones.

5. Primer Information

KAN-2 FP-1 Forward Primer

5' - ACCTACAACAAAGCTCTCATCAACC - 3'

Length: 25 nucleotides

G+C content: 11

Molecular Weight: 7,484 daltons

Temperatures of Dissociation & Melting:

T_d : 68°C (nearest neighbor method)

T_m : 73°C (% G+C method)

T_m : 72°C ($[2(A+T) + 4(G+C)]$ method)

T_m : 63°C ($((81.5 + 16.6(\log [Na^+])) +$
 $([41(\#G+C) - 500] / \text{length})$ method)
where $[Na^+] = 0.1$ M

R6KAN-2 RP-1 Reverse Primer

5' - CTACCCTGTGGAACACCTACATCT - 3'

Length: 24 nucleotides

G+C content: 12

Molecular Weight: 7,210 daltons

Temperatures of Dissociation & Melting:


T_d : 66°C (nearest neighbor method)

T_m : 74°C (% G+C method)

T_m : 72°C ($[2(A+T) + 4(G+C)]$ method)

T_m : 65°C ($((81.5 + 16.6(\log [Na^+])) +$
 $([41(\#G+C) - 500] / \text{length})$ method)
where $[Na^+] = 0.1$ M

EZ-Tn5™ <R6K_γ ori / KAN-2> Transposon
(2001 bp.)



Note: Not all restriction enzymes that cut only once are indicated above.

See the following pages for further information.

Primers are not drawn to scale.

R6KAN-2 RP-1 Reverse Primer

KAN-2 FP-1 Forward Primer

ME = Mosaic End

5' CTACCCTGTGGAACACCTACATCT 3'

5' ACCTACAACAAAGCTCTCATCAACC 3'

5' AGATGTGTATAAGAGACAG 3'

Figure 2. EZ-Tn5 <R6K_γori/KAN-2> Transposon.

Restriction Enzymes that cut the EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon 1 to 3 times:

Enzyme	Sites	Location	Enzyme	Sites	Location
Acc I	1	1952	Fau I	2	673, 1928
Apo I	2	962, 1146	Fsp I	2	709, 807
Ase I	2	339, 1548	Hae I	2	719, 1436
AsiS I	1	1349	Hae II	1	521
Ava I	2	736, 947	Hae III	3	719, 953, 1436
Ava II	3	681, 723, 1902	Hinc II	1	1953
BamH I	1	1939	Hind III	2	416, 1969
Ban II	1	1004	Mly I	2	1582, 1958
Bbs I	1	568	Msc I	1	719
Bfa I	2	674, 1946	Msl I	2	508, 703
BfrB I	2	1197, 1463	Nci I	2	679, 1222
BfuA I	1	1964	Nla IV	3	682, 725, 1941
Bpu10 I	2	581, 1366	Nru I	1	1006
BsaA I	3	176, 198, 308	Nsi I	2	1199, 1465
BsaB I	1	95	Nsp I	1	1967
BsaW I	3	99, 497, 1484	PaeR7 I	1	947
BsiE I	1	1349	PflM I	2	798, 1612
BsiHKA I	1	700	Ple I	2	1581, 1957
Bsm I	3	808, 1233, 1310	PpuM I	2	681, 723
BsmB I	1	1365	Psi I	1	385
Bsp1286 I	2	700, 1004	Pst I	1	1961
BspD I	2	29, 1040	Pvu I	1	1349
BspE I	2	99, 497	Sal I	1	1951
BspH I	1	867	Sau96 I	3	681, 723, 1902
BspM I	1	1964	Sbf I	1	1961
BsrD I	1	841	Sfc I	1	1957
BsrF I	1	1303	Sim I	2	681, 723
BstDS I	3	718, 1873, 1934	Sml I	1	947
Btg I	3	714, 1869, 1930	SnaB I	1	176
Bts I	2	1210, 1297	Sph I	1	1967
Cla I	2	29, 1040	Ssp I	1	1274
Dra I	1	414	Sty I	1	792
Dra III	1	818	Tli I	1	947
Dsa I	3	714, 1869, 1930	Tsp45 I	1	1496
Eae I	1	717	TspRI	3	1222, 1297, 1769
Ear I	1	1162	Xba I	1	1945
EcoN I	1	1261	Xho I	1	947
EcoO109 I	2	681, 723	Xmn I	1	38

Restriction Enzymes that cut the EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon 4 or more times:

Aci I	Cac8 I	HpyCH4 IV	Rsa I
Alu I	CviJ I	HpyCH4 V	Sau3A I
Alw I	Dde I	Mae II	ScrFI
BsaJ I	Dpn I	Mae III	SfaNI
Bsl I	Fnu4H I	Mbo I	Taq I
BsmA I	Hha I	Mbo II	Tfi I
Bsr I	Hinf I	Mnl I	Tse I
BssK I	HinP I	Mse I	Tsp4C I
BstF5 I	Hpa II	Msp I	Tsp509 I
BstNI	Hph I	Mwo I	
BstUI	Hpy188 I	Nla III	
BstY I	HpyCH4 III	PspGI	

Restriction Enzymes that do not cut the EZ-Tn5 <R6K_{Yori}/KAN-2> Transposon:

Aat II	Bcl I	BstB I	Nae I	SanDI
Acc65 I	Bgl I	BstE II	Nar I	Sap I
Acl I	Bgl II	BstXI	Nco I	Sca I
Afe I	Blp I	BstZ17 I	Nde I	SexA I
Afl II	Bme1580 I	Bsu36 I	NgoM IV	Sfi I
Afl III	BmgB I	Drd I	Nhe I	Sfo I
Age I	Bmr I	Eag I	Not I	SgrA I
Ahd I	Bsa I	Eco47 III	Pac I	Sma I
Ale I	BsaH I	EcoR I	Pci I	Spe I
AlwNI	BseY I	EcoR V	PfiFI	Srf I
Apa I	BsiW I	Fse I	Pme I	Sse8647 I
ApaB I	BspLU11 I	Gdi II	Pml I	Stu I
ApaL I	BsrB I	Hpa I	PshA I	Swa I
Asc I	BsrD I	Hpy99 I	PspOM I	Tat I
Avr II	BsrG I	Kpn I	Pvu II	Tth111 I
Ban I	BssH II	Mfe I	Rsr II	Xcm I
BbvC I	BssS I	Mlu I	Sac I	Xma I
BciV I	BstAP I	MspA1 I	Sac II	

EZ-Tn5™ <R6K_{Yori}/KAN-2> Transposon 2,001 bp.

1 CTGTCCTTTA TACACATCTC AACCATCATC GATGAATTGC TTTCGTTAATA CAGATGTAGG TGTTCACAGC
 71 GGTAGCCAGC AGCATCTTCG GATGCAGATC CGGATGCCAT TTCAATTACT CTTTCTCCGC ACCGCACATA
 141 GATCCGAAGA TCAGCAGTTC AACCTGTTGA TAGTACGGTAC TAAGCTCTCA TGTTCACCGT ACTAAGTCT
 211 CATGTTTAACTACTAAGCT CTCATGTTTTA ACGAACTAAA CCCTCATGGC TAACGTACTA AGCTCTCATG
 281 GCTAACGTAC TAAAGCTCTCA TGTTTCACGT ACTAAGCTCT CATGTTTCAA CAATAAAAT AATATAAATC
 351 AGCAACTTAA ATAGCCTCTA AGGTTTTAAG TTTTATAAGA AAAAAAGAA TATATAAGC TTTTAAAGT
 421 TTTAAGGTTT AACGGTTGTG GACAACAAGC CAGGATCTG CCATTTCAAT ACCTTTTCT CCGCACCGA
 491 CATAGATCCG GAACATAATG GTGCAGGGCG CTGACTTCCG CGTTTCCAGA CTTTACGAAA CACGGAAACC
 561 GAAAGACCATT CATGTTGTTG CTCAGGTCGC AGACGTTTTG CAGCAGCAGT CGCTTTCAGT TCGCTCGCGT
 631 ATFCGGTGATT CATTCGTCTA ACCAGTAAGG CAACCCCGCC AGCCTAGCCG GGTCTCAAC GACAGAGCA
 701 CGATCATGCG CACCCGTGGC CAGGACCCAA CGTTCGCCGA GATGCGCGC GTCCGGTGC TGGAGATGGC
 771 GGACGCGATG GATATGTTCT GCCAAGGTTT GGTTTCCGGA TTCAACAGGT GTCTCAAAAT CTCTGATGTT
 841 ACAATTGCACA AGATAAAAAT ATATCATCAT GAACAATAAA ACTGTCTGCT TACATAAACA GTAATAAAGT
 911 GGTGTTTATG AGCCATAATC AACGGGAAAC GTCTTGCTCG AGGCCCGCAT TAAATTCAAA CATGGATGCT
 981 GATTTATATG GGTATAAATG GGCTCGCGAT AATGTCGGGC AATCAGGTGC GACAATCTAT CGATTTGATG
 1051 GGAAGCCCGA TCGCCAGAG TTGTTTCTGA AACATGGCAA AGGTAGCGTT GCCAATGATG TTACAGATGA
 1121 GATGGTCAGA CTAAACTGGC TGACGGAAAT TATGCTCTTT CCGACCATCA AGCATTTTAT CCGTACTCCT
 1191 GATGATGCAT GGTACTCAC CACTGCGATC CCGGAAAAA CAGCATTTCA GGTATTAGAA GAATACTCTG
 1261 ATTCAGGTGA AAATAATTGT GATGCGCTGG CAGTGTCTCT GCGCCGGTTG CATTCGATTC CTGTTTGTAA
 1331 TTGTCCTTTT AACAGCGATC CGGTATTTCC TCTCGCTCAG GCGCAATCAC GAATGAATAA CCGTTTGGTT
 1401 GATGCGAGTG ATTTTATGA CAGCGTAAAT GGCTGGCCTG TTGAACAAGT CTGGAAGAA ATGCAATAAC
 1471 TTTTGCCATT CTCACCGGAT TCAGTCGTCA TCTATGGTGA TTTTCTCATT GATAACCTTA TTTTTCACGA
 1541 GGGAAATTA ATAGTTTGA TTGATGTTGG ACGAGTCGGA ATCGCAGACC GATACCAGGA TCTTTCGATC
 1611 CTATGGAATC GCCTCGGTGA GTTTTCTCCT TCATTACAGA AACGGCTTTT TCAAAAATAT GGTATTGATA
 1681 ATCTGTATAT GAATAAATG CAGTTTCAAT TGATGCTCGA TGAGTTTTTC TAATCAGAA TGGTTAATTG
 1751 GTTGTAAAC TGGCAGAGCA TTACGCTGAC TTGACGGGAC GCGGGCTTTG TTGAATAAAT CGAACTTTG
 1821 CTGAGTTGAA GGATCAGATC ACGCATCTTC CCGACAACCG AGACCGTTC GTGGCAAAGC AAAAGTTCAA
 1891 AATCACCAAC TGGTCCACCT ACAACAAAGC TCTCATCAAC CGTGGCGGGG ATCTCTCTAGA GTCGACCTGC
 1961 AGGCATGCAA GCTTCAGGGT TGAGATGTGT ATAAGAGACA G

The transposon sequence can be downloaded at www.lucigen.com/sequences

6. References

1. Hoffman, L.M. and Jendrisak, J. (1999) *Epicentre Forum*, **6** (3), 1.
2. Goryshin, I.Y. et al., (2000) *Nat. Biotechnol.* **18**, 97.
3. Metcalf, W.W. et al., (1994) *Gene*, **138**, 1.

EC100D, End-It, EZ-Tn5, Fast-Link, and TransforMax are trademarks of Lucigen.

Transposome is a trademark of Epicentre, Madison, Wisconsin.

Triton is a registered trademark of Rohm & Haas, Philadelphia, Pennsylvania.

'Use of Transposome™ Complexes for in vivo Transposon Insertion, including, but not limited to EZ-Tn5™ Transposome™ complexes, is covered by U.S. Patent Nos. 6,159,736 and 6,294,385; European Patent No. 1115856 and other patents issued or pending, exclusively licensed to Epicentre. These products are accompanied by a limited non-exclusive license for nonprofit organizations to use the purchased products solely for life science research. Specifically, researchers at nonprofit organizations may use these products in their research and they may transfer derivatives of the products to colleagues at other nonprofit organizations provided that such colleagues agree in writing to be bound by the terms and conditions of this label license. Researchers may not transfer these products or its derivatives to researchers at other organizations that are not nonprofit organizations without the express written consent of Epicentre and without those entities having an express license from Epicentre for the use of the products. Other than as specifically provided here, an authorized transferee of these products shall have no right to transfer these products or its derivatives to any other person or entity. A nonprofit organization performing research using this product for a for-profit organization shall also be considered for-profit. For-profit entities purchasing these products shall have three (3) months to evaluate the products in their research. Thereafter, such for-profit entities shall either contact Epicentre and take a license for their continued use of the products or destroy the products and all derivatives thereof. Please contact Epicentre with respect to licenses for commercial use, including manufacturing, therapeutic or diagnostic use.